Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations.

Authors :: Forbes LR
Vogel TP
Cooper MA
Castro-Wagner J
Schussler E
Weinacht KG
Plant AS
Su HC
Allenspach EJ
Slatter M
Abinun M
Lilic D
Cunningham-Rundles C
Eckstein O
Olbrich P
Guillerman RP
Patel NC
Demirdag YY
Zerbe C
Freeman AF
Holland SM
Szabolcs P
Gennery A
Torgerson TR
Milner JD
Leiding JW
Source :: The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2018 Nov; Vol. 142 (5), pp. 1665-1669. Date of Electronic Publication: 2018 Aug 06.
Publication Year :: 2018

Subjects :: Adolescent
Adult
Child
Female
Gain of Function Mutation
Humans
Immunologic Deficiency Syndromes drug therapy
Male
Nitriles
Piperidines therapeutic use
Protein Kinase Inhibitors therapeutic use
Pyrazoles therapeutic use
Pyrimidines therapeutic use
Pyrroles therapeutic use
Treatment Outcome
Immunologic Deficiency Syndromes genetics
Janus Kinases antagonists & inhibitors
STAT1 Transcription Factor genetics
STAT3 Transcription Factor genetics

Full Text Access

Tools